Navigation Links
Purple corn compound may aid in developing future treatments for Type 2 diabetes, kidney disease
Date:9/18/2012

BETHESDA, Md. (Sept. 18, 2012)Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S. The maize is rich in anthocyanins (also known as flavonoids), which are reported to have anti-diabetic properties. Scientists from the Department of Food and Nutrition and Department of Biochemistry at Hallym University in Korea investigated the cellular and molecular activity of purple corn anthocyanins (PCA) to determine whether and how it affects the development of diabetic nephropathy (DN). Their findings suggest that PCA inhibits multiple pathways involved in the development of DN, which may help in developing therapies aimed at type 2 diabetes and kidney disease.

The study is entitled "Purple corn anthocyanins inhibit diabetes-associated glomerular monocyte activation and macrophage infiltration" http://bit.ly/SlrkRY. It appears in the online edition of the American Journal of Physiology Renal Physiology, published by the American Physiological Society (APS; www.the-aps.org).

Methodology

Researcher Min-Kyung Kang and colleagues performed a two-part study, an in vitro experiment investigating the effects of PCA on human endothelial cells cultured under hyperglycemic kidney conditions and an in vivo study that investigated the effects of PCA on kidney tissue in diabetic mice. In the in vitro experiment, cultured cells were exposed to 1-20 g/ml of PCA for six hours (control cells were not exposed), then assessed for level of monocyte-endothelial cell adhesion, a major factor in the development of diabetic glomerulosclerosis. In the in vivo experiment, diabetic and control mice were dosed with PCA for eight weeks, then changes in kidney tissue were assessed and immunohistological analyses were performed. Kidney tissue was further analyzed for levels of inflammatory chemokines, which are key components in DN.

Results

Researchers found that in human endothelial cells cultured in hyperglycemic kidney conditions, induction of endothelial cell adhesion molecules decreased in a dose-dependent manner with PCA exposure, meaning that the PCA likely interfered with cell-cell adhesion in glomeruli. PCA also appeared to interfere with leukocyte recruitment and adhesion to glomerular endothelial cells. In diabetic mice, PCA exposure slowed mesangial expansion and interrupted the cellular signaling pathway that may instigate glomerular adhesion and infiltration of inflammatory cells responsible for diabetic glomerulosclerosis. Finally, PCA inhibited levels of macrophage inflammatory protein-2 and monocyte chemotactic protein-1 in kidney tissue, demonstrating that it may inhibit macrophage infiltration, which is closely related to renal inflammation.

Importance of the Findings

The research suggests that anthocyanins may be the main biofunctional compound in purple corn and could protect against mesangial activation of monocytes and infiltration of macrophages in glomerulithe two major contributors to DN. The research further suggests that renoprotection by PCA against mesangial activation may be specific therapies targeting diabetes-associated diabetic glomerulosclerosis and renal inflammation. Finally, PCA supplementation may be an important strategy in preventing renal vascular disease in type 2 diabetes.

"PCA may be a potential renoprotective agent treating diabetes-associated glomerulosclerosis," wrote the researchers.


'/>"/>

Contact: Donna Krupa
dkrupa@the-aps.org
American Physiological Society
Source:Eurekalert

Related biology news :

1. Screening technique uncovers 5 new plant activator compounds
2. Mushroom-derived compound lengthens survival in dogs with cancer, Penn Vet study finds
3. Compound discovered that boosts effect of vaccines against HIV and flu
4. MMV develops framework to assess risk of resistance for antimalarial compounds
5. Compounds shown to thwart stubborn pathogens social propensity
6. University of Albertas designer compounds inhibit prion infection
7. Scripps Research scientists show potent new compound virtually eliminates HIV in cell culture
8. Poisoning from industrial compounds can cause similar effects to ALS
9. New compound holds promise for treating Duchenne MD, other inherited diseases
10. Nonstoichiometric Compounds V - An ECI Conference Series
11. New drug-screening method yields long-sought anti-HIV compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , ... March 23, 2017 , ... ... material that exhibits both viscous and elastic characteristics when deformed, which is identical ... exhibits properties to gently absorb compressive forces and return to its natural state ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseqâ„¢ ... developed with input from industry experts to ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
Breaking Biology Technology: